Clinical Trials Browser

NCT02465060 2026-04-13

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT06385483 2026-04-07

Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)

Phase 2 Active not recruiting

19 enrolled 10 charts

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT05070403 2026-04-01

Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma

Phase 2 Recruiting

25 enrolled

Dermatologic

Carcinoma, Squamous Cell, Skin Neoplasms

Clinical Trials

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)

Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma

Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck

A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.

Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC

Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous NSCLC

Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)

neoCHANCE-1

Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC

neoCHANCE-2

Afatinib in Advanced Refractory Urothelial Cancer

COMBINATION

Afatinib in NSCLC With HER2 Mutation

Primary Tumor Resection With EGFR TKI for Stage IV NSCLC

Afatinib in Locally Advanced and Metastatic Chordoma

Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.

Afatinib With CT and RT for EGFR-Mutant NSCLC

Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA

BEAR

Afatinib in Advanced NRG1-Rearranged Malignancies

NSCLC

DRUP

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations

DARWIN1

UPSTREAM

Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer

AFACET

A Study of Afatinib in Patients With Advanced Cancer With Changes in the HER Gene

Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence

Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal Junction

Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung Cancer

Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer

Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma

TRUMP

ACE-Lung

BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer

ALPHA

BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC

Efficacy and Safety of Precision Therapy in Refractory Tumor

PREDICTOR

LiquidLung-A

Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification

Gilotrif (Afatinib) in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib

LUX-Lung-IO

LUX-Bladder 1

A Biomarker-implemented Clinical Study Evaluating Mutations in MET and TP53 in a Population of Treatment-refractory Squamous Cell Carcinoma

Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation

HER2BAT